ABSTRACT
OBJECTIVES: The study aimed to assess if specialised healthcare service interventions in Wales benefit the population equitably in work commissioned by the Welsh Health Specialised Services Committee (WHSSC). APPROACH: The study utilised anonymised individual-level, population-scale, routinely collected electronic health record (EHR) data held in the Secure Anonymised Information Linkage (SAIL) Databank to identify patients resident in Wales receiving specialist cardiac interventions. Measurement was undertaken of associated patient outcomes 2-years before and after the intervention (minus a 6-month clearance period on either side) by measuring events in primary care, hospital attendance, outpatient and emergency department. The analysis controlled for comorbidity (Charlson) and deprivation (Welsh Index of Multiple Deprivation), stratified by admission type (elective or emergency) and membership of top 5% post-intervention costs. Costs were estimated by multiplying events by mean person cost estimates. RESULTS: We identified 5,999 percutaneous coronary interventions (PCI) and 1,640 coronary artery bypass graft (CABG) between 2014-06-01 to 2020-02-29. The ratio of emergency to elective interventions was 2.85 for PCI and 1.04 for CABG. In multivariate analysis significant associations were identified for comorbidity (OR = 1.52, CI = (1.01-2.27)), deprivation (OR = 1.34, CI = (1.03-1.76)) and rurality (OR = 0.81, CI = (0.70-0.95)) for PCI interventions, and comorbidity (OR = 1.47, CI = (1.10-1.98)) for CABG. Higher costs post-intervention were associated with increased comorbidity for PCI and CABG in the top 5% cost groups, but for PCI this was not seen outside the top 5%. For PCI, moderate cost increase was associated with increased deprivation, but the picture was more mixed following CABG interventions. For both interventions, lower costs post intervention were seen in rural locations. CONCLUSION: We identified and compared health outcomes for selected specialist cardiac interventions amongst patients resident in Wales, with these methods and analyses, providing a template for comparing other cardiac interventions.
Subject(s)
Coronary Artery Disease , Percutaneous Coronary Intervention , Humans , Coronary Artery Disease/surgery , Percutaneous Coronary Intervention/adverse effects , Wales/epidemiology , State Medicine , Treatment OutcomeABSTRACT
We describe the novel use of oral chloramphenicol for treatment-resistant Mycoplasma genitalium (M. genitalium) infection in a 20-year-old heterosexual cisgender male presenting with recurrent symptomatic non-gonococcal urethritis. M. genitalium urethritis is an increasingly common clinical conundrum in sexual health clinics and in cases of second-line treatment failure (such as moxifloxacin), UK and international guidelines struggle to make recommendations for third-line treatments. As shown in our case, the evidence base for third-line treatments is lacking, with poor success rates, and may be poorly tolerated. Here we demonstrate the novel use of a well-tolerated oral antimicrobial, chloramphenicol, resulting in rapid microbiological and clinical cure in treatment-resistant M. genitalium urethritis.
Subject(s)
Anti-Infective Agents , Mycoplasma Infections , Mycoplasma genitalium , Urethritis , Humans , Male , Young Adult , Adult , Urethritis/drug therapy , Urethritis/microbiology , Chloramphenicol/therapeutic use , Mycoplasma Infections/drug therapy , Mycoplasma Infections/microbiology , Anti-Infective Agents/therapeutic use , Anti-Bacterial Agents/therapeutic use , Drug Resistance, BacterialABSTRACT
BACKGROUND: Eye disease and visual impairment are common in the elderly and are associated with social and functional decline, the need to access community support services, depression, falls, nursing home placement and increased mortality. OBJECTIVE: To provide guidance for general practitioners in the detection and recommended management of the most important eye conditions in the elderly in Australia: refractive error, cataract, diabetic retinopathy, age-related macular degeneration and glaucoma. DISCUSSION: Timely detection and treatment of eye disease can greatly reduce its morbidity. Elderly patients should be encouraged to undergo eye testing every 2 years. Health professionals, including general practitioners, optometrists and ophthalmologists should work collaboratively to ensure patients have access to appropriate disease detection and treatment.
Subject(s)
Eye Diseases , General Practice/methods , Ophthalmology/methods , Age Factors , Aged , Australia/epidemiology , Eye Diseases/diagnosis , Eye Diseases/epidemiology , Eye Diseases/therapy , Humans , Morbidity/trends , Risk FactorsABSTRACT
Protein endoglycosidases are useful for biocatalytic alteration of glycans on protein surfaces, but the currently limited selectivity of endoglycosidases has prevented effective manipulation of certain N-linked glycans widely found in nature. Here we reveal that a bacterial endoglycosidase from Streptococcus pyogenes , EndoS, is complementary to other known endoglycosidases (EndoA, EndoH) used for current protein remodeling. It allows processing of complex-type N-linked glycans +/- core fucosylation but does not process oligomannose- or hybrid-type glycans. This biocatalytic activity now addresses previously refractory antibody glycoforms.
Subject(s)
Glycoproteins/metabolism , Glycoside Hydrolases/metabolism , Polysaccharides/metabolism , Glycoproteins/chemistry , Glycoside Hydrolases/chemistry , Humans , Immunoglobulin G/chemistry , Immunoglobulin G/metabolism , Models, Molecular , Protein Conformation , Streptococcus pyogenes/enzymology , Substrate SpecificityABSTRACT
The human gut microbiota harbors three main groups of H(2)-consuming microbes: methanogens including the dominant archaeon, Methanobrevibacter smithii, a polyphyletic group of acetogens, and sulfate-reducing bacteria. Defining their roles in the gut is important for understanding how hydrogen metabolism affects the efficiency of fermentation of dietary components. We quantified methanogens in fecal samples from 40 healthy adult female monozygotic (MZ) and 28 dizygotic (DZ) twin pairs, analyzed bacterial 16S rRNA datasets generated from their fecal samples to identify taxa that co-occur with methanogens, sequenced the genomes of 20 M. smithii strains isolated from families of MZ and DZ twins, and performed RNA-Seq of a subset of strains to identify their responses to varied formate concentrations. The concordance rate for methanogen carriage was significantly higher for MZ versus DZ twin pairs. Co-occurrence analysis revealed 22 bacterial species-level taxa positively correlated with methanogens: all but two were members of the Clostridiales, with several being, or related to, known hydrogen-producing and -consuming bacteria. The M. smithii pan-genome contains 987 genes conserved in all strains, and 1,860 variably represented genes. Strains from MZ and DZ twin pairs had a similar degree of shared genes and SNPs, and were significantly more similar than strains isolated from mothers or members of other families. The 101 adhesin-like proteins (ALPs) in the pan-genome (45 ± 6 per strain) exhibit strain-specific differences in expression and responsiveness to formate. We hypothesize that M. smithii strains use their different repertoires of ALPs to create diversity in their metabolic niches, by allowing them to establish syntrophic relationships with bacterial partners with differing metabolic capabilities and patterns of co-occurrence.
Subject(s)
Adhesins, Bacterial/genetics , Gastrointestinal Tract/microbiology , Genome, Archaeal , Methanobrevibacter/genetics , Twins , Adult , Base Sequence , Female , Formates/analysis , Humans , Metagenomics , Methanobrevibacter/metabolism , Molecular Sequence Data , Polymorphism, Single Nucleotide/genetics , RNA, Ribosomal, 16S/genetics , Sequence Analysis, DNA , Species SpecificityABSTRACT
AIMS: To characterize photopsia in posterior vitreous detachment (PVD), retinal tears (RT) and rhegmatogenous retinal detachment (RRD). METHODS: Seventy seven patients presenting to an eye emergency department and vitreoretinal clinic with photopsia had documentation of their symptoms. RESULTS: A total of 27 patients had PVD alone, 7 had RTs and 25 RRD. In patients with isolated PVD, photopsia were temporal (94%), lasting seconds (81%) and vertically orientated (59%) flashes. Patients with photopsia located in quadrants other than temporal were more likely to have RRD (p = 0.0003). Patients with an oblique or horizontal orientation of their photopsia were likely to have RRD or RT (p = 0.001, specificity 96%, sensitivity 40%). CONCLUSIONS: Most patients with PVD have a typical presentation of photopsia, with temporal, vertically orientated, momentary flashes. Patients with RTs or RRD may describe subtle differences in their photopsia which may raise the index of suspicion for the presence of a complication from PVD.
Subject(s)
Retinal Detachment/complications , Retinal Perforations/complications , Vision Disorders/etiology , Vitreous Detachment/complications , Aged , Aged, 80 and over , Color , Female , Humans , Light , Male , Middle Aged , Prospective Studies , Vision Disorders/diagnosisSubject(s)
Anterior Chamber/pathology , Lens Capsule, Crystalline/pathology , Lens Nucleus, Crystalline/pathology , Lens Subluxation/etiology , Phacoemulsification/adverse effects , Corneal Edema/etiology , Gonioscopy , Humans , Lens Nucleus, Crystalline/surgery , Lens Subluxation/pathology , Lens Subluxation/surgery , Postoperative Period , Reoperation , Treatment OutcomeABSTRACT
PURPOSE: To report the prevalence of intraocular lens (IOL) opacification and related clinical features in patients implanted with Hydroview IOL. SETTING: Gloucestershire Eye Unit, Gloucestershire, United Kingdom. METHODS: A total of 1330 eyes of 1265 patients who had cataract surgery with Hydroview IOL implantation between September 2000 and April 2001 were reviewed between April and October 2004. The visual acuity, visual symptoms, IOL status, and associated ocular comorbidity were recorded. RESULTS: One hundred ninety-three (14.5%) of 1330 eyes had evidence of IOL opacification. A total of 56 (4.2%) had visually significant opacification and had IOL exchange. The prevalence of IOL opacification ranged from 1.1% in patients who had surgery in September 2000 to 36.3% in the December 2000 group. In eyes with IOL opacification, the visual symptoms were decreased vision (57%), glare (32%), and mistiness of vision (27%). One hundred forty-four eyes (75%) with IOL opacification had visual acuity of 6/12 or better; 21.5% of diabetic eyes had IOL opacification compared with 14.3% of nondiabetic eyes (P =.06); 20.5% of glaucomatous eyes had IOL opacification compared with 14.0% of nonglaucomatous eyes (P = .033). CONCLUSIONS: This is the first large sample recall of patients implanted with the Hydroview H60M IOL. The overall prevalence of IOL opacification was 14.5%, with peak prevalence in patients who had surgery in December 2000.
Subject(s)
Acrylic Resins , Lens Implantation, Intraocular , Lenses, Intraocular/statistics & numerical data , Phacoemulsification , Prosthesis Failure , Vision Disorders/epidemiology , Adult , Aged , Aged, 80 and over , Comorbidity , Female , Humans , Male , Middle Aged , Prevalence , Reoperation , United Kingdom/epidemiology , Vision Disorders/etiology , Vision Disorders/physiopathology , Visual Acuity/physiologyABSTRACT
AIMS: To test whether measuring hyperaemic changes in pulse wave velocity (PWV) could be used as a new method of assessing endothelial function for use in clinical practice. METHODS AND RESULTS: Flow-mediated changes in vascular tone may be used to assess endothelial function and may be induced by distal hyperaemia, while endothelium-mediated changes in vascular tone can influence PWV. These three known principles were combined to provide and test a novel method of measuring endothelial function by the acute effects of distal hyperaemia on upper and lower limb PWV (measured by a recently developed method). Flow-mediated changes in upper and lower limb PWV were compared in 17 healthy subjects and seven patients with stable chronic heart failure (CHF), as a condition where endothelial function is impaired but endothelium-independent dilator responses are retained. Corroborative measurements of PWV and brachial artery diameter responses to endothelium-dependent and -independent pharmacological stimuli were performed in a further eight healthy subjects. Flow-mediated reduction of PWV (by 14% with no change in blood pressure) was found in normal subjects but was almost abolished in patients with CHF. PWV responses appear to be inversely related to and relatively greater than brachial artery diameter responses. CONCLUSION: The method may offer potential advantages of practical use and sensitivity over conduit artery diameter responses to measure endothelial dysfunction.
Subject(s)
Arteries/physiopathology , Blood Flow Velocity/physiology , Endothelium, Vascular/physiopathology , Heart Failure/physiopathology , Myocardial Ischemia/physiopathology , Adult , Arm/blood supply , Brachial Artery/physiopathology , Heart Failure/etiology , Humans , Leg/blood supply , Male , Middle Aged , Myocardial Ischemia/complications , Punctures , Vasodilation/drug effects , Vasodilator Agents/pharmacologyABSTRACT
Experimental hyperhomocysteinemia after an oral methionine or homocysteine load is associated with impaired nitric oxide-dependent vasodilatation in healthy human beings. However, it remains unproven that this effect is mediated by elevations in plasma homocysteine. There is evidence that an increase in plasma homocysteine may increase the formation of asymmetric dimethylarginine (ADMA), an inhibitor of nitric oxide synthase. The methyl groups within ADMA are derived from the conversion of S -adenosylmethionine to S -adenosylhomocysteine intermediates in the methionine/homocysteine pathway. No previous study has assessed the role of methylation status, its impact on ADMA formation, and their association with endothelial function in healthy human beings. In a randomized, placebo-controlled, crossover study, 10 healthy subjects (mean age, 29.1 +/- 3.9 years) were administered an oral dose of methionine (0.1 g/kg), l -homocysteine (0.01 g/kg), N-acetylcysteine (NAC) (0.1 g/kg), or placebo. Endothelial function as assessed by flow-mediated dilatation (FMD) of the brachial artery was impaired after both the methionine and homocysteine load compared with placebo at 4 hours (36 +/- 15, 67 +/- 23 vs 219 +/- 26 microm, respectively, P < .001). N-Acetylcysteine had no effect on flow-mediated dilatation. Plasma total homocysteine was significantly elevated at 4 hours after methionine (23.1 +/- 6.2) and homocysteine (41.5 +/- 8.9) loading, but significantly reduced after NAC 2.4 +/- 0.6 vs 7.1 +/- 2.1 micromol/L in the placebo (P < .001). Plasma S-adenosylmethionine/S-adenosylhomocysteine ratio was significantly (P < .001) increased at 4 hours after methionine (10.9 +/- 0.7) compared with homocysteine (5.4 +/- 0.4), NAC (5.0 +/- 0.3), and placebo (6.0 +/- 0.5). Plasma ADMA concentrations were not altered by any intervention. Our results suggest that endothelial dysfunction due to methionine or homocysteine loading is not associated with an increase in plasma ADMA or a disruption in methylation status.
Subject(s)
Arginine/analogs & derivatives , Arginine/blood , Endothelium, Vascular/physiopathology , Homocysteine/blood , Hyperhomocysteinemia/blood , S-Adenosylhomocysteine/blood , S-Adenosylmethionine/blood , Acetylcysteine/administration & dosage , Adult , Blood Flow Velocity , Brachial Artery , Cross-Over Studies , Cystathionine/blood , Cysteine/blood , Dipeptides/blood , Double-Blind Method , Female , Homocysteine/administration & dosage , Humans , Kinetics , Male , Methionine/administration & dosage , Methionine/blood , Placebos , VasodilationABSTRACT
BACKGROUND AND OBJECTIVE: Endothelial dysfunction is an early, pre-clinical manifestation of coronary heart disease and is associated with increased plasma levels of von Willebrand factor (vWF), soluble E-selectin, and thrombomodulin, markers of endothelial cell damage/activation and reduced nitric oxide bioavailability. Homocysteine is associated with an increased risk of cardiovascular disease and mortality. High-dose folic acid treatment lowers plasma homocysteine by 25% and improves nitric oxide bioavailability; however, the effects on other indices of endothelial cell activation/damage has not been examined in patients with coronary heart disease and normal renal function. DESIGN AND METHODS: In a randomised, double-blind, cross-over study in 50 patients with coronary heart disease and normal serum creatinine, folic acid (5 mg/daily) was administered for 6 weeks and blood was analysed for von Willebrand factor, soluble E-selectin, and thrombomodulin. Endothelial nitric oxide bioavailability was assessed by flow-mediated dilatation. RESULTS: Plasma folate levels increased (9.1+/-3.4 vs. 310+/-235 microg/l; p<0.001) and nitric oxide bioavailability improved (47+/-35 vs. 110+/-43 microm; p<0.001) following active treatment. However, markers of endothelial cell injury were not significantly influenced (von Willebrand factor 118+/-33 vs. 119+/-34%; E-selectin 52+/-17 vs. 51+/-16 microg/l; thrombomodulin 3.94+/-1.81 vs. 3.94+/-1.51 microg/l; p=NS comparing post-placebo with post-folate). No correlation was observed between improvement in flow-mediated dilatation and change in endothelial marker proteins. INTERPRETATION AND CONCLUSION: These data suggest that endothelial markers are not useful surrogates of endothelial nitric oxide bioavailability in coronary heart disease and may be a less sensitive marker of endothelial function than nitric oxide.
Subject(s)
Coronary Disease/physiopathology , Endothelium, Vascular/drug effects , Folic Acid/pharmacology , Hematinics/pharmacology , Vasodilation/drug effects , Aged , Biomarkers/blood , Cross-Over Studies , Double-Blind Method , E-Selectin/blood , Female , Humans , Male , Middle Aged , Nitric Oxide/metabolism , Thrombomodulin/blood , Time Factors , Vasodilation/physiology , von Willebrand Factor/analysisABSTRACT
Evidence reported from numerous clinical studies over the past decade has revealed an association between increased plasma total homocysteine (tHcy) concentrations and cardiovascular disease (CVD). In addition, epidemiological studies have identified an inverse association between blood folate concentrations, folate intake and cardiovascular endpoints, that are independent of homocysteine. Folic acid supplementation can lower plasma tHcy concentrations safely and inexpensively. Furthermore, folic acid can reverse endothelial dysfunction observed in patients with CVD. This reversal in endothelial dysfunction with folic acid has been shown to be independent of plasma tHcy lowering, suggesting that folate has pleiotropic effects on the vasculature other than homocysteine lowering. In vitro evidence demonstrates that 5-methyltetrahydrofolate (5MeTHF) the main circulating metabolite of folate, can increase nitric oxide production and can directly scavenge superoxide radicals. The potential beneficial role of folic acid supplements on vascular disease are currently being tested in randomized placebo controlled studies.
Subject(s)
Cardiovascular Diseases/physiopathology , Endothelium, Vascular/physiopathology , Folic Acid/physiology , Homocysteine/physiology , Antioxidants , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/etiology , Endothelium, Vascular/drug effects , Folic Acid/adverse effects , Folic Acid/pharmacology , Folic Acid Deficiency/complications , Humans , Hyperhomocysteinemia/epidemiology , Hyperhomocysteinemia/etiology , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type III , Risk Factors , Vitamin B Complex/therapeutic useSubject(s)
Ascorbic Acid/administration & dosage , Coronary Disease/drug therapy , Radial Artery/drug effects , Administration, Oral , Case-Control Studies , Coronary Disease/diagnosis , Dose-Response Relationship, Drug , Female , Humans , Male , Radial Artery/physiology , Risk Assessment , Treatment Failure , Vasodilator Agents/administration & dosageABSTRACT
Elevated plasma homocysteine is associated with increased cardiovascular risk but it remains unproven that the effect is directly causal. Folate and homocysteine metabolism are closely linked such that administration of folic acid in doses ranging from 0.2-10 mg/day lowers plasma total homocysteine (tHcy) by up to 25%. Folic acid has been widely advocated as a therapy which may reduce cardiovascular risk, but the clinical benefit remains as yet unproven and the choice of dose remains unclear. The effect of folic acid on endothelial function has been investigated in patients with proven coronary heart disease (CHD) by measuring flow-mediated dilatation (FMD) in the brachial artery. Oral folic acid (5 mg/day) markedly enhances endothelial function (FMD) and lowers homocysteine. Studies of the acute effects of folic acid have shown that this improvement occurs within the first 2-4 hours following the first dose, at which times there was no significant reduction in plasma tHcy. Administration of 5-methyltetrahydrofolate directly into the brachial artery markedly enhances FMD, an effect that is blocked by monomethyl arginine (LNMMA), suggesting that the effects of folate are mediated by nitric oxide. This Review summarises studies which show that pharmacological doses of folate markedly enhance endothelial function in patients with CHD. The discordance with changes in plasma homocysteine suggests that these effects may occur by mechanisms distinct from homocysteine lowering.
Subject(s)
Coronary Disease/drug therapy , Endothelium, Vascular/drug effects , Folic Acid/therapeutic use , Vasodilation/drug effects , Administration, Oral , Brachial Artery/drug effects , Brachial Artery/physiology , Coronary Disease/blood , Coronary Disease/physiopathology , Cross-Over Studies , Double-Blind Method , Endothelium, Vascular/physiology , Female , Folic Acid/administration & dosage , Homocysteine/blood , Humans , Infusions, Intra-Arterial , Male , Middle Aged , Regional Blood Flow/drug effects , Tetrahydrofolates/administration & dosage , Tetrahydrofolates/therapeutic use , Vasodilation/physiologyABSTRACT
The time course of acute changes in large artery distensibility immediately and for 60 min following maximum treadmill exercise in normal subjects was characterized by simultaneously measuring upper and lower limb pulse wave velocity (PWV). A new oscillometric technique was used, which has proven to be sensitive to changes in distensibility induced by acute changes in vascular tone independently of blood pressure. The observed changes in PWV are attributable to changes in vascular tone corresponding to recovery from a systemic net constrictor response and a local net dilator response to exercise with persisting postexercise vasodilatation. They are inadequately explained by associated changes in blood pressure and cannot be attributed to changes in heart rate or viscosity. Modeled as a system of n coupled linear differential equations, the minimum (and adequate) order required to reproduce these patterns was n = 1 for the upper and n = 2 for the exercising lower limb. The economy of the solution suggests entrainment among the multiple interactive mechanisms governing vasomotor control.
Subject(s)
Arteries/physiology , Physical Exertion/physiology , Vasodilation/physiology , Adolescent , Adult , Arm/blood supply , Blood Pressure/physiology , Exercise Test , Female , Heart Rate/physiology , Humans , Leg/blood supply , Male , Middle Aged , Models, Cardiovascular , Pulsatile Flow/physiology , Reference Values , Time FactorsSubject(s)
Cardiovascular Diseases/drug therapy , Folic Acid/administration & dosage , Homocysteine/blood , Homocysteine/drug effects , Cardiovascular Diseases/blood , Cardiovascular Diseases/prevention & control , Clinical Trials as Topic , Endothelium, Vascular/drug effects , Female , Humans , Male , Prognosis , Sensitivity and Specificity , Treatment OutcomeABSTRACT
BACKGROUND: Homocysteine is a risk factor for coronary artery disease (CAD), although a causal relation remains to be proven. The importance of determining direct causality rests in the fact that plasma homocysteine can be safely and inexpensively reduced by 25% with folic acid. This reduction is maximally achieved by doses of 0.4 mg/d. High-dose folic acid (5 mg/d) improves endothelial function in CAD, although the mechanism is controversial. It has been proposed that improvement occurs through reduction in total (tHcy) or free (non-protein bound) homocysteine (fHcy). We investigated the effects of folic acid on endothelial function before a change in homocysteine in patients with CAD. METHODS AND RESULTS: A randomized, placebo-controlled study of folic acid (5 mg/d) for 6 weeks was undertaken in 33 patients. Endothelial function, assessed by flow-mediated dilatation (FMD), was measured before, at 2 and 4 hours after the first dose of folic acid, and after 6 weeks of treatment. Plasma folate increased markedly by 1 hour (200 compared with 25.8 nmol/L; P<0.001). FMD improved at 2 hours (83 compared with 47 microm; P<0.001) and was largely complete by 4 hours (101 compared with 51 microm; P<0.001). tHcy did not significantly differ acutely (4-hour tHcy, 9.56 compared with 9.79 micromol/L; P=NS). fHcy did not differ at 3 hours but was slightly reduced at 4 hours (1.55 compared with 1.78 micromol/L; P=0.02). FMD improvement did not correlate with reductions in either fHcy or tHcy at any time. CONCLUSIONS: These data suggest that folic acid improves endothelial function in CAD acutely by a mechanism largely independent of homocysteine.
Subject(s)
Coronary Artery Disease/drug therapy , Endothelium, Vascular/drug effects , Folic Acid/therapeutic use , Hematinics/therapeutic use , Homocysteine/drug effects , Coronary Artery Disease/blood , Coronary Artery Disease/physiopathology , Double-Blind Method , Endothelium, Vascular/physiopathology , Female , Folic Acid/blood , Hematinics/blood , Homocysteine/blood , Humans , Male , Middle Aged , Tetrahydrofolates/blood , Time Factors , Treatment Outcome , Vasodilation/physiologyABSTRACT
The relationship between somatotype and somatotype components with coronary artery disease (CAD) and regional adiposity was considered in 58 males (age 60.2 +/- 9.4 years) undergoing investigative coronary angiography for suspected atherosclerotic CAD. Severity of CAD was determined in terms of both the degree of stenosis and the anatomical position of the lesions on the coronary arteries (myocardial score). Six patients had negative angiographic findings but three of these had impaired left ventricular function as determined by left ventriculography. The mean (+/-SD) somatotype of the group was 5.7 / 5.6 / 1.2 (1.7 / 1.4 / 1.0), illustrating a clear dominance of the first two somatotype components. Canonical correlation analysis showed that somatotype was not significantly related to the angiography results (P > 0.05). However, correlations between the somatotype components and the angiography results with their respective first canonical variates showed that the somatotype variate was one of high mesomorphy and low ectomorphy and the angiography variate was essentially one of a high myocardial score. After adjustment for the confounding interrelationship among the somatotype components, endomorphy was significantly correlated with abdominal circumference (r = 0.65, P < 0.001), the abdomen-to-hip ratio (r = 0.53, P < 0.001) and the abdominal sagittal diameter (r = 0.60, P < 0.001). Mesomorphy was not related to these indicators of android or abdominal adiposity following partial adjustment. Ectomorphy was inversely related to the indices of general and regional adiposity. This study suggests that adiposity and muscularity are important features in terms of increased CAD risk, whereas linearity is beneficial. Am. J. Hum. Biol. 12:128-138, 2000. Copyright 2000 Wiley-Liss, Inc.